Trial Profile
Phase 1, Open-label, Single-dose Study of Evolocumab (AMG 145) Administered Subcutaneously to Subjects With Normal Renal Function or Severe Renal Impairment or End Stage Renal Disease Receiving Hemodialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Amgen
- 01 Jan 2019 Results evaluating the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9, published in the Clinical Pharmacology in Drug Development.
- 05 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov